Adding Sorafenib to Chemo Combo Fails to Improve Metastatic Melanoma Survival

No improvement in overall survival was seen in patients with metastatic melanoma who were assigned treatment with sorafenib in combination with carboplatin/paclitaxel for the treatment of their disease, according to the results of a double-blind, phase III study.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news